Clinical Trials Browser

Phase 2 × Lymphoma, Large B-Cell, Diffuse × Nivolumab × Clear all

NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT04205409 2026-05-12

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Phase 2 Completed

20 enrolled 12 charts

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03749018 2026-02-06

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Active not recruiting

30 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03484819 2025-03-03

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Phase 2 Completed

12 enrolled 13 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse